CD5L induces inflammation and survival in RA-FLS through ERK1/2 MAPK pathway

Figures & data

Table 1. Primers for reverse transcription-polymerase chain reaction.

Name of gene	Forward primer	Reverse primer	Product size (bp)
IL-6	5′-GAGTAGTGAGGAACAAGCCAGAG-3′	5′-GGTCAGGGGTGGTTATTGC-3′	104
IL-8	5′-TTGGCAGCCTTCCTGATTTC-3′	5′-GGGTGGAAAGGTTTGGAGTATG-3′	110
TNF-α	5′-GCCCATGTTGTAGCAAACCC-3′	5′ -TCTGGTAGGAGACGGCGATG-3′	226
BAX	5′-CCTCCTCTCCTACTTTGGGAC-3′	5′-GAAAAACACAGTCCAAGGCAG-3′	130
BCL2	5′-GTGGCCTTCTTTGAGTTCGG-3′	5′- GGTGCCGGTTCAGGTACTCA- 3′	112
GAPDH	5′-CACTCCTCCACCTTTGACGC-3′	5′-CTGTTGCTGTAGCCAAATTCGT-3′	98

IL-6, interleukin 6, IL-8, interleukin 8, TNF-α, tumour necrosis factor-α, BCL2, B cell lymphoma 2, BAX, BCL2-Associated X, GAPDH, glyceraldehyde-3-phosphate dehydrogenase; bp, base pair.

Figure 1. Expression of CD55 and CD36 in RA-FLS cells. A: CD55 molecule in RA-FLS. B: CD36 molecule in RA-FLS. The cells that don’t add Alexa Fluor 555 as a negative control to exclude false positive caused by cell self-fluorescence interference (×200 magnification).

Figure 3. CD5L activated ERK1/2 MAPK signaling pathway. Cells (5 × 10⁶) were challenged with CD5L protein (500 ng/mL) for different times(0, 30, 60, 90 min). The protein was extracted and the expression levels of phosphorylation signal molecules (A) p-p38 MAPK, p-AKT, p-JAK, and p-I κB-α and (B) p-ERK were detected by WB.

Figure 5. Effect of inhibitor on CD5L activation of ERK1/2 MAPK signaling pathway. Cells (5 × 10⁶) were treated with ERK1/2 inhibitor U0126 for 1 h, and then added CD5L protein for 90 min. Protein was extracted, and the expression level of phosphorylated signal molecule p-ERK1/2 MAPK was detected by WB. GAPDH was used to correct the protein content of each sample.

Data availability

The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.